Viridian Therapeutics (NASDAQ:VRDN) Director Fairmount Funds Management Llc Purchases 454,545 Shares

Viridian Therapeutics, Inc. (NASDAQ:VRDN) Director Fairmount Funds Management Llc acquired 454,545 shares of the firm’s stock in a transaction that occurred on Thursday, October 23rd. The shares were purchased at an average cost of $22.00 per share, with a total value of $9,999,990.00. Following the completion of the acquisition, the director owned 3,914,458 shares in the company, valued at $86,118,076. This trade represents a 13.14% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Viridian Therapeutics Price Performance

NASDAQ VRDN opened at $22.54 on Tuesday. The company has a current ratio of 11.01, a quick ratio of 11.01 and a debt-to-equity ratio of 0.04. The company has a fifty day simple moving average of $20.25 and a 200 day simple moving average of $16.82. The company has a market cap of $1.84 billion, a P/E ratio of -5.89 and a beta of 0.49. Viridian Therapeutics, Inc. has a 1 year low of $9.90 and a 1 year high of $27.20.

Viridian Therapeutics (NASDAQ:VRDN) last posted its quarterly earnings data on Wednesday, August 6th. The company reported ($1.00) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($1.00). The business had revenue of $0.08 million during the quarter, compared to the consensus estimate of $0.05 million. Viridian Therapeutics had a negative net margin of 112,806.88% and a negative return on equity of 78.95%. Viridian Therapeutics’s quarterly revenue was up 4.2% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.81) EPS. On average, sell-side analysts predict that Viridian Therapeutics, Inc. will post -4.03 EPS for the current year.

Analyst Ratings Changes

Several analysts recently issued reports on VRDN shares. Needham & Company LLC decreased their price objective on shares of Viridian Therapeutics from $36.00 to $34.00 and set a “buy” rating for the company in a report on Wednesday, August 6th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Viridian Therapeutics in a research note on Wednesday, October 8th. The Goldman Sachs Group upped their target price on shares of Viridian Therapeutics from $27.00 to $30.00 and gave the company a “buy” rating in a research note on Thursday, August 7th. Jefferies Financial Group assumed coverage on shares of Viridian Therapeutics in a research note on Monday, August 25th. They set a “buy” rating and a $44.00 target price for the company. Finally, Oppenheimer upped their target price on shares of Viridian Therapeutics from $32.00 to $36.00 and gave the company an “outperform” rating in a research note on Tuesday, October 21st. Eight equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $35.38.

Hedge Funds Weigh In On Viridian Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Commodore Capital LP lifted its holdings in shares of Viridian Therapeutics by 35.4% during the 2nd quarter. Commodore Capital LP now owns 4,875,000 shares of the company’s stock worth $68,152,000 after acquiring an additional 1,275,000 shares during the period. Maverick Capital Ltd. lifted its holdings in shares of Viridian Therapeutics by 9.5% during the 2nd quarter. Maverick Capital Ltd. now owns 2,257,010 shares of the company’s stock worth $31,553,000 after acquiring an additional 195,736 shares during the period. Paradigm Biocapital Advisors LP lifted its holdings in shares of Viridian Therapeutics by 15.1% during the 1st quarter. Paradigm Biocapital Advisors LP now owns 2,095,079 shares of the company’s stock worth $28,242,000 after acquiring an additional 275,000 shares during the period. Geode Capital Management LLC lifted its holdings in shares of Viridian Therapeutics by 1.2% during the 2nd quarter. Geode Capital Management LLC now owns 1,740,614 shares of the company’s stock worth $24,337,000 after acquiring an additional 20,089 shares during the period. Finally, Goldman Sachs Group Inc. lifted its holdings in shares of Viridian Therapeutics by 33.8% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,231,092 shares of the company’s stock worth $16,595,000 after acquiring an additional 310,998 shares during the period.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.